RESUMO
Lithium is a cation, similar to sodium and potassium, affecting ion transport. It is used in the medical field as a treatment of bipolar disorders. The main endocrine complications of lithium treatment affect thyroid and parathyroid glands, in association with renal complications. Thyroid adverse effects, which are more frequent in women, comprise hypothyroidism, goiter, or sometimes hyperthyroidism, through interference with the iodine symporter. The increase in thyroid volume is early. Prevalence of goiter is 4 times higher than in the general population and hypothyroidism (8-20%) more frequent in case of pre-existing thyroid autoimmunity. Hyperthyroidism likely to worsen mood is reported in 5% of cases but the causal link to lithium is unproven. An increase in serum calcium and PTH occurs in 30% of cases, as lithium stimulates parathyroid cell proliferation by activating the Wnt pathway. The risk of hyperparathyroidism, by adenoma and especially by hyperplasia, is 5 times higher than in the general population, with the particularity of frequent low urine calcium by action on the calcium-sensing receptor (CaSR). Renal complications include risk of acute or chronic renal failure and nephrogenic diabetes insipidus, which is a factor for hypernatremia and hypercalcemia through dehydration. Nephrogenic diabetes insipidus is not always reversible after lithium therapy discontinuation. Metabolically, weight gain can be observed, but rather less than with other psychotropic drugs, and lithium does not in itself induce diabetes. At pituitary level, corticotropic activation is frequent, but implicating the disease rather than lithium. Lithium treatment induces little or no hyperprolactinemia. Regular monitoring of serum calcium, the ionogram, creatinine and TSH is recommended in lithium treatment.
Assuntos
Diabetes Insípido Nefrogênico , Bócio , Hipertireoidismo , Hipotireoidismo , Humanos , Feminino , Lítio/efeitos adversos , Diabetes Insípido Nefrogênico/induzido quimicamente , Cálcio , Compostos de Lítio/efeitos adversos , Hipotireoidismo/induzido quimicamente , Bócio/induzido quimicamente , Doença Iatrogênica/epidemiologiaRESUMO
The association between glucagon-like peptide-1 (GLP-1) receptor agonists and the risk of various kinds of thyroid disorders remains uncertain. We aimed to evaluate the relationship between the use of GLP-1 receptor agonists and the occurrence of 6 kinds of thyroid disorders. We searched PubMed (MEDLINE), EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL) and Web of Science from database inception to 31 October 2021 to identify eligible randomized controlled trials (RCTs). We performed meta-analysis using a random-effects model to calculate risk ratios (RRs) and 95% confidence intervals (CIs). A total of 45 trials were included in the meta-analysis. Compared with placebo or other interventions, GLP-1 receptor agonists' use showed an association with an increased risk of overall thyroid disorders (RR 1.28, 95% CI 1.03-1.60). However, GLP-1 receptor agonists had no significant effects on the occurrence of thyroid cancer (RR 1.30, 95% CI 0.86-1.97), hyperthyroidism (RR 1.19, 95% CI 0.61-2.35), hypothyroidism (RR 1.22, 95% CI 0.80-1.87), thyroiditis (RR 1.83, 95% CI 0.51-6.57), thyroid mass (RR 1.17, 95% CI 0.43-3.20), and goiter (RR 1.17, 95% CI 0.74-1.86). Subgroup analyses and meta-regression analyses showed that underlying diseases, type of control, and trial durations were not related to the effect of GLP-1 receptor agonists on overall thyroid disorders (all P subgroup > 0.05). In conclusion, GLP-1 receptor agonists did not increase or decrease the risk of thyroid cancer, hyperthyroidism, hypothyroidism, thyroiditis, thyroid mass and goiter. However, due to the low incidence of these diseases, these findings need to be examined further. Systematic Review Registration: PROSPERO https://www.crd.york.ac.uk/prospero/, identifier: CRD42021289121.
Assuntos
Diabetes Mellitus Tipo 2 , Bócio , Hipertireoidismo , Hipotireoidismo , Neoplasias da Glândula Tireoide , Diabetes Mellitus Tipo 2/complicações , Receptor do Peptídeo Semelhante ao Glucagon 1/agonistas , Bócio/induzido quimicamente , Bócio/complicações , Bócio/tratamento farmacológico , Humanos , Hipertireoidismo/induzido quimicamente , Hipoglicemiantes/uso terapêutico , Hipotireoidismo/tratamento farmacológico , Ensaios Clínicos Controlados Aleatórios como Assunto , Neoplasias da Glândula Tireoide/tratamento farmacológicoRESUMO
Lithium is an efficient treatment of bipolar disorder. Besides renal insufficiency, many endocrine side effects are described such as the occurrence of thyroid disorders, hypercalcaemia and nephrogenic diabetes insipidus. Lithium inhibits the secretion of thyroid hormones. The prevalence of goiter is 4 times more common in Lithium-treated patients compared as to the general population. Hypothyroidism (8-20%) is more frequent in women and in case of pre-existing thyroid autoimmunity. Grave's disease and other hyperthyroidisms are sometimes reported. Lithium stimulates the proliferation of parathyroid cells by activating the Wnt pathway. An increase in serum calcium and PTH is described in patients treated with Lithium with a 4 to 6-fold higher risk of primary hyperparathyroidism than in the general population. Nevertheless, 24-hour urine calcium is not often increased, and the phenotype can mimic a hypercalcemia-hypocalciuria syndrome that may regress with Lithium discontinuation. Surgery should be cautious since parathyroid hyperplasia is more common than parathyroid adenoma. Nephrogenic diabetes insipidus is frequently reported and may be debilitating, sometimes intricated with severe dehydration, hypernatremia, and acute renal insufficiency. Nephrogenic diabetes insipidus is not generally reversible after Lithium discontinuation, especially in patients who have chronic kidney disease due to interstitial tubule nephritis. In conclusion, clinical assessment (goiter, diuresis) and biological monitoring of serum calcium, sodium creatinine, TSH and lithium are recommended in patients receiving Lithium therapy. The risk of Lithium discontinuation in case of side effects should be weighed against the psychological risk, and must be discussed with the psychiatrist.
Assuntos
Diabetes Insípido Nefrogênico , Bócio , Hipercalcemia , Hiperparatireoidismo , Cálcio , Diabetes Insípido Nefrogênico/induzido quimicamente , Diabetes Insípido Nefrogênico/tratamento farmacológico , Diabetes Insípido Nefrogênico/epidemiologia , Endocrinologistas , Feminino , Bócio/induzido quimicamente , Bócio/tratamento farmacológico , Bócio/epidemiologia , Humanos , Hipercalcemia/induzido quimicamente , Hipercalcemia/tratamento farmacológico , Hipercalcemia/epidemiologia , Hiperparatireoidismo/tratamento farmacológico , Lítio , Compostos de Lítio/efeitos adversosRESUMO
La enfermedad por coronavirus SARS-CoV-2 que surgió en el año 2019 (COVID-19), ha obligado al rápido desarrollo de vacunas para prevenir su propagación e intentar controlar la pandemia. Dentro de las vacunas desarrolladas, las primeras en ser aprobadas con una tecnología nueva en el campo de la vacunación, fueron las vacunas basadas en ARNm (ácido ribonucleico mensajero), que lograron tasas de efectividad cercanas al 95 % para la prevención de la enfermedad COVID-19 grave. Los eventos adversos comunes son reacciones locales leves, pero ha habido varios informes de pacientes que desarrollaron tiroiditis subaguda y disfunción tiroidea después de recibir la vacuna contra SARS-CoV-2. Este artículo presenta dos casos de tiroiditis subaguda poco después de recibir la vacuna contra COVID-19
The SARS-CoV-2 coronavirus disease which emerged in 2019 (COVID-19), has forced the rapid development of vaccines to prevent the spread of infection and attempt to control the pandemic. Among the vaccines developed, one of the first to be approved with a new technology in the field of vaccination, was the mRNA (messenger ribonucleic acid) vaccine, with rates of effectiveness close to 95% for the prevention of severe COVID-19 disease. Common adverse events are mild local reactions, but there have been some reports of patients developing sub-acute thyroiditis and thyroid dysfunction after receiving the SARS-CoV-2 vaccine. This article presents two case reports of subacute thyroiditis shortly after receiving the COVID-19 vaccine
Assuntos
Humanos , Masculino , Feminino , Adulto , Idoso , Tireoidite Subaguda/induzido quimicamente , Tireotoxicose/induzido quimicamente , Vacina BNT162/efeitos adversos , ChAdOx1 nCoV-19/efeitos adversos , Tireoidite Subaguda/diagnóstico , Tireoidite Subaguda/tratamento farmacológico , Tireotoxicose/diagnóstico , Tireotoxicose/tratamento farmacológico , Anti-Inflamatórios não Esteroides/uso terapêutico , Bócio/induzido quimicamenteRESUMO
Previous studies have demonstrated that, in addition to inducing structural changes in thyroid follicles, cadmium (Cd) increased the number of C cells. We examined the effects of myo-inositol (MI), seleno-L-methionine (Se), MI + Se, and resveratrol on C cells of mice exposed to cadmium chloride (Cd Cl2), as no data are currently available on the possible protective effects of these molecules. In contrast, we have previously shown this protective effect against CdCl2 on the thyroid follicles of mice. Ninety-eight C57 BL/6J adult male mice were divided into 14 groups of seven mice each: (i) 0.9% NaCl (vehicle; 1 ml/kg/day i.p.); (ii) Se (0.2 mg/kg/day per os); (iii) Se (0.4 mg/kg/day per os); (iv) MI (360 mg/kg/day per os); (v) Se (0.2 mg/kg/day) + MI; (vi) Se (0.4 mg/kg/day) + MI; (vii) resveratrol (20 mg/kg); (viii) CdCl2 (2 mg/kg/day i.p.) + vehicle; (ix) CdCl2 + Se (0.2 mg/kg/day); (x) CdCl2 + Se (0.4 mg/kg/day); (xi) CdCl2 + MI; (xii) CdCl2 + Se (0.2 mg/kg/day) + MI; (xiii) CdCl2 + Se (0.4 mg/kg/day) + MI; (xiv) CdCl2 + resveratrol (20 mg/kg). After 14 days, thyroids were processed for histological, immunohistochemical, and morphometric evaluation. Compared to vehicle, Cd significantly decreased follicle mean diameter, increased CT-positive cells number, area and cytoplasmic density, and caused the disappearance of TUNEL-positive C cells, namely, the disappearance of C cells undergoing apoptosis. Se at either 0.2 or 0.4 mg/kg/day failed to significantly increase follicular mean diameter, mildly decreased CT-positive cells number, area and cytoplasmic density, and was ineffective on TUNEL-positive C cells. Instead, MI alone increased significantly follicular mean diameter and TUNEL-positive cells number, and decreased significantly CT-positive cells number, area and cytoplasmic density. MI + Se 0.2 mg/kg/day or MI + Se 0.4 mg/kg/day administration improved all five indices more markedly. Indeed, follicular mean diameter and TUNEL-positive cells number increased significantly, while CT-positive cells number, area and cytoplasmic density decreased significantly. Thus, all five indices overlapped those observed in vehicle-treated mice. Resveratrol improved significantly all the considered parameters, with a magnitude comparable to that of MI alone. In conclusion, the association Myo + Se is effective in protecting the mouse thyroid from the Cd-induced hyperplasia and hypertrophy of C cells. This benefit adds to that exerted by Myo + Se on thyrocytes and testis.
Assuntos
Cádmio/farmacologia , Inositol/farmacologia , Selênio/farmacologia , Glândula Tireoide/efeitos dos fármacos , Animais , Tamanho Celular/efeitos dos fármacos , Bócio/induzido quimicamente , Bócio/patologia , Hiperplasia/induzido quimicamente , Hipertrofia/induzido quimicamente , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Tamanho do Órgão/efeitos dos fármacos , Células Epiteliais da Tireoide/citologia , Células Epiteliais da Tireoide/efeitos dos fármacos , Glândula Tireoide/citologia , Glândula Tireoide/patologiaRESUMO
The study was primarily aimed at investigating the effect of brassica sprout consumption, namely rutabaga (Brassica napus L. var. napobrassica) sprouts (R) generally recognized as antithyroid agent due to its goitrogenic substance content, on hematological, biochemical, and immunological parameters in rats. Sprouts were tested alone and in a combination with other antithyroid factors, such as iodine deficiency (RDI) and sulfadimethoxine (RS). The expression of the heme oxygenase-1 (HO-1) gene in the thyroid as a stress-inducible protein was determined. The thermographic analysis was also estimated. The intake of rutabaga sprouts by healthy rats did not reveal any significant, harmful effect on the thyroid function. Both body temperature and expression of HO-1 remained unchanged in response to the consumed sprouts. In animals with hypothyroidism, rutabaga sprouts enhanced the negative effect of iodine deficiency or sulfadimethoxine ingestion on the organism by increasing the WBC (RDI), TNF-α (RS), creatinine (RS), and triglyceride (RDI and RS) levels, as well as decreasing PLT (RS) level. Moreover, rutabaga sprout consumption by rats with iodine deficiency and sulfadimethoxine decreased their body temperature. Additionally, the concomitant administration of sprouts and iodine depletion significantly reduced the expression of HO-1 in the thyroid. The results may prove useful in confirming rutabaga sprout consumption to be safe, though the seeds of this vegetable provide a well-known antithyroid agent. Our results have shown that rutabaga sprout consumption may be also a factor that enhances the negative clinical features only when combined with iodine deficiency and sulfadimethoxine ingestion.
Assuntos
Brassica napus , Bócio , Iodo/deficiência , Plântula , Sulfadimetoxina/farmacologia , Glândula Tireoide/metabolismo , Animais , Creatinina/sangue , Modelos Animais de Doenças , Bócio/sangue , Bócio/induzido quimicamente , Bócio/dietoterapia , Heme Oxigenase (Desciclizante)/metabolismo , Contagem de Leucócitos , Masculino , Ratos , Ratos Endogâmicos F344 , Glândula Tireoide/lesões , Glândula Tireoide/patologia , Triglicerídeos/sangue , Fator de Necrose Tumoral alfa/sangueRESUMO
INTRODUCTION: Epoprostenol, a synthetic prostaglandin I2 (PGI2) analog, has been the mainstay of treatment for severe pulmonary arterial hypertension (PAH) for the last two decades. Treprostinil, another synthetic prostaglandin analog, and selexipag, an oral selective Inositol Phosphate (IP) prostacyclin receptor agonist, have also been approved for treatment of PAH. Prostacyclin and its analogs cause a variety of side effects in patients with PAH; however, thyroid dysfunction is rarely reported. METHODS: After treating an index case of thyroid dysfunction occurring after initiation of epoprostenol, we reviewed our databases of PAH patients treated with epoprostenol, treprostinil or selexipag to identify the occurrence of this association. RESULTS: We identified six cases of thyroid dysfunction in our cohort: five after initiation of an intravenous prostacyclin (epoprostenol) and one after initiation of an oral prostacyclin receptor agonist (selexipag). Four of the patients presented with hyperthyroidism and two with a large autoimmune goiter. Graves' disease was seen in three patients, Hashimoto's disease in two patients and thyrotoxicosis in one patient. CONCLUSION: Therapy with medications targeting the prostacyclin pathway is a potential risk factor for the development of symptomatic thyroid disease.
Assuntos
Acetamidas/efeitos adversos , Anti-Hipertensivos/efeitos adversos , Epoprostenol/efeitos adversos , Bócio/induzido quimicamente , Hipertireoidismo/induzido quimicamente , Hipertensão Arterial Pulmonar/tratamento farmacológico , Pirazinas/efeitos adversos , Tireoidite Autoimune/induzido quimicamente , Adulto , Idoso , Feminino , Doença de Graves/induzido quimicamente , Doença de Hashimoto/induzido quimicamente , Humanos , Masculino , Tireotoxicose/induzido quimicamenteAssuntos
Meios de Contraste/efeitos adversos , Bócio/congênito , Histerossalpingografia/efeitos adversos , Iodo/efeitos adversos , Efeitos Tardios da Exposição Pré-Natal/diagnóstico por imagem , Adulto , Feminino , Bócio/induzido quimicamente , Bócio/diagnóstico por imagem , Humanos , Recém-Nascido , Infertilidade Feminina , Masculino , GravidezRESUMO
Occurrence and mode of action of potentially relevant goitrogens in human nutrition and their mode of action (MOA) are reviewed, with special focus on the anionic iodine uptake inhibitors perchlorate (PER), thiocyanate (SCN) and nitrate (NO3). Epidemiological studies suggest persistent halogenated organic contaminants and phthalates as well as certain antimicrobials to deserve increased attention. This also applies to natural goitrogens, including polyphenols and glucosinolates, food constituents with limited data density concerning human exposure. Glucosinolates present in animal feed are presumed to contribute to SCN transfer into milk and milk products. PER, SCN and NO3 are well-investigated environmental goitrogens in terms of MOA and relative potency. There is compelling evidence from biomarker monitoring that the exposure to the goitrogens SCN and NO3 via human nutrition exceeds that of PER by orders of magnitude. The day-to-day variation in dietary intake of these substances (and of iodide) is concluded to entail corresponding variations in thyroidal iodide uptake, not considered as adverse to health or toxicologically relevant. Such normal variability of nutritional goitrogen uptake provides an obvious explanation for the variability in radioactive iodine uptake (RAIU) measurements observed in healthy individuals. Based on available data, a 20 % change in the thyroidal uptake of iodide is derived as threshold value for a biologically meaningful change induced by perchlorate and other goitrogens with the same MOA. We propose this value to be used as the critical effect size or benchmark response in benchmark dose analysis of human RAIU data. The resulting BMDL20 is 0.0165 mg/kg bw/day or 16.5 µg/kg bw/day. Applying a factor of 4, to allow for inter-human differences in toxicokinetics, leads to a TDI for perchlorate of 4 µg/kg bw/day.
Assuntos
Poluentes Ambientais/toxicidade , Contaminação de Alimentos/análise , Bócio/induzido quimicamente , Glândula Tireoide/efeitos dos fármacos , Benchmarking , Biomarcadores/metabolismo , Bócio/metabolismo , Humanos , Medição de Risco , Glândula Tireoide/metabolismoAssuntos
Antineoplásicos/efeitos adversos , Neoplasias da Mama/terapia , Bócio/induzido quimicamente , Tireoidite Autoimune/induzido quimicamente , Trastuzumab/efeitos adversos , Adulto , Autoanticorpos/sangue , Biomarcadores/sangue , Neoplasias da Mama/patologia , Quimioterapia Adjuvante , Progressão da Doença , Evolução Fatal , Feminino , Bócio/diagnóstico , Bócio/imunologia , Humanos , Mastectomia Radical Modificada , Metástase Neoplásica , Tireoidite Autoimune/diagnóstico , Tireoidite Autoimune/imunologia , Fatores de Tempo , Resultado do TratamentoRESUMO
Endemic fluorosis is a serious problem in public health. Previous studies have indicated that patients with thyroid goiters usually live in fluoride-affected areas. However, the mechanism of goitrogenesis caused independently by fluoride is still unclear. The principle objective of this study was to investigate the possible roles of nitric oxide (NO) and vascular endothelial growth factor (VEGF) in the genesis of fluoride-induced nodular goiters. Eighty SD rats (40 males and 40 females) at the age of 4 weeks were used to establish animal models via fluoride-supplemented drinking water. These rats were randomly divided into four groups of 20. Group 1 was used as the control and were given deionized water. Group 2 (LF), group 3 (MF), and group 4 (HF) were given deionized water containing 50mg/L, 100mg/L, and 200mg/L of sodium fluoride (NaF), respectively. Thyroid samples were collected on day 150. Pathological observation was performed to evaluate structural changes in the thyroid gland. The expression of VEGF mRNA in the thyroid glands was assessed by reverse transcriptional PCR. The serum NO level was analyzed by spectrometric methods. In addition, immunohistochemistry was conducted to evaluate expression and deposition of VEGF in the thyroid gland. The results showed that the average relative weight of the thyroid glands of rats in the fluoride-treated groups was significantly higher than that in control rats (p<0.05). The proliferation and dilatation of capillary blood vessels, enlarged follicles with excessive colloid, and obvious nodules were found in the thyroid glands of fluoride-treated rats. Compared to the control group, the expression of VEGF mRNA in the thyroid gland and the serum NO levels in the fluoride-treated groups were significantly increased (p<0.05). Furthermore, the deposition of VEGF in epithelial and follicular cells of the thyroid gland was significantly higher in fluoride-treated groups than in the control group. These results suggested that abnormal expression of VEGF induced by fluoride can lead to the proliferation of vascular endothelial cells in the thyroid gland. Accordingly, VEGF oversecreted locally by vascular endothelial cells might contribute to the proliferation of epithelial and follicular cells, resulting in the formation of hyperplastic nodules and enlargement of the thyroid gland. Furthermore, we proposed that there might be a positive feedback mechanism between NO and VEGF expression in fluoride-induced goiter formation. It was concluded that angiogenic and vasodilative factors such as VEGF and NO must be involved in fluoride-induced thyroid goitrogenesis.
Assuntos
Cariostáticos/toxicidade , Fluoretos/toxicidade , Bócio/metabolismo , Óxido Nítrico/sangue , Fator A de Crescimento do Endotélio Vascular/metabolismo , Animais , Cariostáticos/farmacocinética , Feminino , Fluoretos/sangue , Fluoretos/farmacocinética , Bócio/induzido quimicamente , Masculino , RNA Mensageiro/metabolismo , Ratos , Ratos Sprague-Dawley , Glândula Tireoide/efeitos dos fármacos , Glândula Tireoide/metabolismo , Glândula Tireoide/patologia , Fator A de Crescimento do Endotélio Vascular/genéticaRESUMO
BACKGROUND: We have demonstrated that the administration of delta-iodolactone (i.e., 5-iodo-delta lactone) of arachidonic acid (IL-delta), a mediator in thyroid autoregulation, prevents goiter induction by methylmercaptoimidazol (MMI) in rats. Other studies have shown that transforming growth factor beta-1 (TGF-beta1) mimics some of the actions of excess iodide, but its participation in autoregulation is disputed. The present studies were performed to test the hypotheses that IL-delta decreases thyroid growth by inhibition of cell proliferation and/or by stimulation of apoptosis due to oxidative stress, that TGF-beta is stimulated by an excess of iodide and by IL-delta, and that c-Myc and c-Fos expression are upregulated during goiter induction and downregulated during goiter inhibition. METHODS: Rats were treated with MMI alone or together with iodide or IL-delta. Thyroid weight, cell number, cell proliferation, apoptosis, and oxidative stress were determined. Proliferating cell nuclear antigen (PCNA), TGF-beta1, TGF-beta3, c-Myc, and c-Fos were measured by Western blot. RESULTS: MMI caused a progressive increase in thyroid weight accompanied by an increase in cell number, asymmetry of the ploidy histograms, and PCNA, c-Fos, and c-Myc expression. In addition, an early increase of apoptosis was observed. Peroxides as well as glutathione peroxidase and catalase activities were also increased in goitrous animals. The inhibitory action of IL-delta on goiter formation was accompanied by the inhibition of cell proliferation evidenced by a significant decrease in cell number, PCNA expression, and asymmetry of the ploidy histograms. A transient stimulation of apoptosis after 7 days of treatment was also observed. MMI administration stimulated TGF-beta1 but not TGF-beta3 synthesis. IL-delta alone caused a slight increase of TGF-beta3 but not TGF-beta1, whereas potassium iodide (KI) stimulated both isoforms and MMI reversed KI effect on TGF-beta1 expression but not on TGF-beta3. CONCLUSIONS: The goiter inhibitory action of IL-delta is due to the inhibition of cell proliferation and the transient stimulation of apoptosis. This latter action does not involve oxidative stress. TGF-beta1 does not play a role in the autoregulatory pathway mediated by IL-delta. Iodide stimulates TGF-beta3 without the need of being organified. These results suggest that there may be more than one pathway involved in the autoregulatory mechanism.
Assuntos
Ácidos Araquidônicos/uso terapêutico , Bócio/prevenção & controle , Animais , Apoptose/efeitos dos fármacos , Catalase/análise , Proliferação de Células/efeitos dos fármacos , Feminino , Glutationa Peroxidase/análise , Bócio/induzido quimicamente , Metimazol/toxicidade , Estresse Oxidativo/efeitos dos fármacos , Peróxidos/análise , Antígeno Nuclear de Célula em Proliferação/análise , Proteínas Proto-Oncogênicas c-fos/análise , Proteínas Proto-Oncogênicas c-myc/análise , Ratos , Ratos Wistar , Glândula Tireoide/efeitos dos fármacos , Glândula Tireoide/metabolismo , Fator de Crescimento Transformador beta1/análise , Fator de Crescimento Transformador beta3/análiseRESUMO
Catechins are flavonoids found in abundance in green tea, have elicited high interest due to their beneficial effects on health. Though flavonoids have been reported to have an antithyroid effect and also to be goitrogenic there have been no reports about the effect of green tea on rat thyroid. The present study was designed to examine whether high doses of green tea has any harmful effect on thyroid physiology. For this purpose green tea extract was administered orally to male albino rats for 30 days at doses of 1.25 g%, 2.5 g% and 5.0 g%, respectively. Similarly, pure catechin was administered at doses of 25, 50 and 100mg/kg body weight which is equivalent to above doses of green tea extract. Lower body weight gain associated with marked hypertrophy and/or hyperplasia of the follicles was noted in the high dose of green tea and catechin treated groups. Decreased activity of thyroid peroxidase and 5'-deiodinase I and substantially elevated thyroidal Na,K+ATPase activity have been observed. Moreover, serum T3 and T4 levels were found to reduce followed by significant elevation of serum TSH. Taken together, these results suggest that catechin present in green tea extract might behave as antithyroid agent and possibly the consumption of green tea at high dose could alter thyroid function adversely.
Assuntos
Antitireóideos/farmacologia , Antitireóideos/toxicidade , Catequina/farmacologia , Catequina/toxicidade , Bócio/induzido quimicamente , Chá/química , Animais , Antitireóideos/química , Peso Corporal/efeitos dos fármacos , Catequina/química , Ensaio de Imunoadsorção Enzimática , Iodeto Peroxidase/sangue , Iodeto Peroxidase/metabolismo , Tamanho do Órgão/efeitos dos fármacos , Extratos Vegetais/química , Extratos Vegetais/farmacologia , Extratos Vegetais/toxicidade , Ratos , Ratos Sprague-Dawley , ATPase Trocadora de Sódio-Potássio/sangue , ATPase Trocadora de Sódio-Potássio/metabolismo , Glândula Tireoide/enzimologia , Glândula Tireoide/patologia , Hormônios Tireóideos/sangue , Tiroxina/sangue , Tri-Iodotironina/sangueRESUMO
OBJECTIVES: In this retrospective study, we reviewed the data from patients who had total thyroidectomy for benign thyroid disease and evaluated the safety of this surgery. PATIENTS AND METHODS: Three hundred and twenty three patients (49 males, 274 females; mean age 42.6+/-14.1 years; range 13 to 80 years) who underwent total thyroidectomy between 2002 and 2008 were included in the study. In the preoperative studies, patients with suspicion of thyroid cancer were excluded. Indications for total thyroidectomy, cancer incidence and complication rates were evaluated. Two hundred and eighty three patients (87.6%) were operated on due to bilateral multinodular goiter, 17 (5.3%) due to toxic goiter, 23 (7.1%) due to thyroiditis. RESULTS: In our study, it was found that the incidences of permanent recurrent laryngeal nerve palsy and permanent hypoparathyroidism were 0.6% and 1.86%, respectively. Postoperative hemorrhage requiring repeat surgery occurred in 0.6% of the patients. There was no recurrence during follow-up. CONCLUSION: The present study shows that total thyroidectomy is a safe procedure with a low incidence of permanent complications. Total thyroidectomy is an acceptable surgical alternative for benign multinodular or diffuse goiters.
Assuntos
Doenças da Glândula Tireoide/cirurgia , Tireoidectomia/normas , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Bócio/induzido quimicamente , Bócio/cirurgia , Bócio Nodular/cirurgia , Humanos , Hipoparatireoidismo/epidemiologia , Hipoparatireoidismo/etiologia , Incidência , Masculino , Pessoa de Meia-Idade , Complicações Pós-Operatórias/epidemiologia , Hemorragia Pós-Operatória/etiologia , Hemorragia Pós-Operatória/cirurgia , Reoperação , Estudos Retrospectivos , Segurança , Tireoidectomia/efeitos adversos , Tireoidite/cirurgia , Paralisia das Pregas Vocais/epidemiologia , Paralisia das Pregas Vocais/etiologia , Adulto JovemRESUMO
One in 200 people receive lithium for treatment of bipolar disorder. The common clinical side effects of the drug are goitre in up to 40% and hypothyroidism in about 20%. Lithium increases thyroid autoimmunity if present before therapy. Treatment with levothyroxine is effective and lithium therapy should not be stopped. Lithium may cause hyperthyroidism due to thyroiditis or rarely Graves' disease. As lithium inhibits thyroid hormone release from the thyroid gland it can be used as an adjunct therapy in the management of severe hyperthyroidism. It also increases thyroidal radioiodine retention and may be effective in reducing administered activity in hyperthyroidism. There is no clinical benefit of lithium therapy in thyroid cancer. More research is required on the cellular proliferative effects of lithium as well as its impact on the immune system.
Assuntos
Bócio/induzido quimicamente , Hipertireoidismo/induzido quimicamente , Hipotireoidismo/induzido quimicamente , Compostos de Lítio/uso terapêutico , Glândula Tireoide/efeitos dos fármacos , Animais , Transtorno Bipolar/tratamento farmacológico , Feminino , Bócio/tratamento farmacológico , Humanos , Sistema Hipotálamo-Hipofisário/efeitos dos fármacos , Hipotireoidismo/tratamento farmacológico , Compostos de Lítio/efeitos adversos , Masculino , Glândula Tireoide/fisiologia , Hormônios Tireóideos/metabolismo , Tiroxina/uso terapêuticoRESUMO
OBJECTIVE: To investigate the inhibitory effects of Kangjia Pill (KJP) on the cell proliferation in rat goiter model induced by methimazole (MMI). METHODS: Fifty-six Wistar rats were randomly divided into four groups: the normal group, MMI model group (MMI), low dose of KJP group (LKJP), and high dose of KJP (HKJP). Except the normal group (20 rats), the other groups (12 rats in each) were given 0.04% (w/v) MMI through the drinking water until the end of the experiment. One week later, the rats in the LKJP and HKJP groups were given KJP by gastrogavage at the dose of 250 mg/(kg x d) and 1,000 mg/(kg x d), respectively for 12 weeks. The relative thyroid weight (mg/100 g body weight) of each rat was accessed. The expression of proliferating cell nuclear antigen (PCNA) was determined by immunohistochemistry, and the correlation analysis between the PCNA positive thyrocytes and the relative thyroid weight was performed. The expressions of PCNA and cyclin D1 were examined with Western blotting. RESULTS: After KJP treatment for 12 weeks, compared with the MMI group, the relative thyroid weight of the HKJP group decreased significantly, and the positive thyrocyte populations of PCNA in the two KJP groups reduced markedly (all P<0.05). The correlation analysis showed that PCNA was closely correlated with thyrocyte proliferation (r=0.685, P<0.05). KJP significantly decreased the protein expression of PCNA and cyclin D1 in the thyroid specimens (P<0.05), the high dose showed better effects. CONCLUSION: KJP played a therapeutic role via inhibiting cell proliferation in the rat goitrous glands.
Assuntos
Proliferação de Células/efeitos dos fármacos , Medicamentos de Ervas Chinesas/administração & dosagem , Bócio/tratamento farmacológico , Glândula Tireoide/efeitos dos fármacos , Glândula Tireoide/patologia , Animais , Ciclina D1/metabolismo , Modelos Animais de Doenças , Regulação para Baixo/efeitos dos fármacos , Avaliação Pré-Clínica de Medicamentos , Medicamentos de Ervas Chinesas/farmacologia , Bócio/induzido quimicamente , Bócio/metabolismo , Bócio/patologia , Masculino , Metimazol , Tamanho do Órgão/efeitos dos fármacos , Antígeno Nuclear de Célula em Proliferação/metabolismo , Distribuição Aleatória , Ratos , Ratos Wistar , Comprimidos , Glândula Tireoide/metabolismoRESUMO
Expansion of the thyroid microvasculature is the earliest event during goiter formation, always occurring before thyrocyte proliferation; however, the precise mechanisms governing this physiological angiogenesis are not well understood. Using reverse transcriptase-polymerase chain reaction and immunohistochemistry to measure gene expression and laser Doppler to measure blood flow in an animal model of goitrogenesis, we show that thyroid angiogenesis occurred into two successive phases. The first phase lasted a week and involved vascular activation; this process was thyroid-stimulating hormone (TSH)-independent and was directly triggered by expression of vascular endothelial growth factor (VEGF) by thyrocytes as soon as the intracellular iodine content decreased. This early reaction was followed by an increase in thyroid blood flow and endothelial cell proliferation, both of which were mediated by VEGF and inhibited by VEGF-blocking antibodies. The second, angiogenic, phase was TSH-dependent and was activated as TSH levels increased. This phase involved substantial up-regulation of the major proangiogenic factors VEGF-A, fibroblast growth factor-2, angiopoietin 1, and NG2 as well as their receptors Flk-1/VEGFR2, Flt-1/VEGFR1, and Tie-2. In conclusion, goiter-associated angiogenesis promotes thyroid adaptation to iodine deficiency. Specifically, as soon as the iodine supply is limited, thyrocytes produce proangiogenic signals that elicit early TSH-independent microvascular activation; if iodine deficiency persists, TSH plasma levels increase, triggering the second angiogenic phase that supports thyrocyte proliferation.
Assuntos
Adaptação Fisiológica/fisiologia , Iodo/deficiência , Glândula Tireoide/irrigação sanguínea , Tireotropina/fisiologia , Inibidores da Angiogênese/farmacologia , Animais , Anticorpos Monoclonais/farmacologia , Anticorpos Monoclonais Humanizados , Bevacizumab , Fatores de Crescimento de Fibroblastos/metabolismo , Bócio/induzido quimicamente , Bócio/metabolismo , Indóis/farmacologia , Iodeto Peroxidase/genética , Iodeto Peroxidase/metabolismo , Iodo/farmacologia , Camundongos , Camundongos Endogâmicos , Microcirculação/efeitos dos fármacos , Microcirculação/fisiologia , Neovascularização Fisiológica/efeitos dos fármacos , Percloratos/farmacologia , Pirróis/farmacologia , Testes de Função Tireóidea , Glândula Tireoide/efeitos dos fármacos , Glândula Tireoide/metabolismo , Glândula Tireoide/fisiologia , Tireotropina/metabolismo , Fatores de Tempo , Fator A de Crescimento do Endotélio Vascular/metabolismoRESUMO
OBJECTIVE: The aim of the present study was to analyze the influence of nitrate as a possible alimentary goitrogen on thyroid volume in a previously iodine-deficient area. DESIGN: Population based cross-sectional epidemiologic survey. PARTICIPANTS: Data of 3772 participants (20-79 years) of the Study of Health in Pomerania without diagnosed thyroid disorders were analyzed. EVALUATION AND MEASUREMENTS: The nitrate concentration in spot urine was determined by ion chromatography. High nitrate levels were defined as urine nitrate concentrations exceeding the 75th percentile for the investigated population. Thyroid structure and size were measured by ultrasound. Subjects were divided into two groups with absence or presence of high urine nitrate concentrations. Comparisons between groups were made using the chi(2)-test or the Student's t-test. Multivariable analyses were done by logistic regression and ANOVA (analysis of variance). Odds ratios and their 95% confidence intervals as well as adjusted means (standard error) were calculated. RESULTS: In the whole population, the mean urine nitrate level was 53.1+/-0.8mg/l. The 75th percentile of urine nitrate concentrations was 69.0mg/l, indicating that the renal excretion of nitrate is at a low level. The proportion of goiter in subjects with and without high urine nitrate concentrations was 35.5% and 34.7%, respectively (p=0.69). Analyses considering age, sex and further potential confounders could not identify an association between the exposure variable and the risk of goiter. CONCLUSION: The low level of the alimentary nitrate intake does not influence the thyroid volume in a population with currently sufficient alimentary intake of iodine.
Assuntos
Bócio/induzido quimicamente , Nitratos/efeitos adversos , Tamanho do Órgão/efeitos dos fármacos , Glândula Tireoide/patologia , Adulto , Idoso , Estudos Transversais , Feminino , Alemanha/epidemiologia , Bócio/epidemiologia , Humanos , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Nitratos/urina , Fatores de Risco , Fumar/epidemiologia , Glândula Tireoide/diagnóstico por imagem , UltrassonografiaRESUMO
Insulin receptor substrate-1 (IRS-1) is the main intracellular substrate for both insulin and insulin-like growth factor I (IGF-I) receptors and is critical for cell mitogenesis. Thyrotropin is able to induce thyroid cell proliferation through the cyclic AMP intracellular cascade; however, the presence of either insulin or IGF-I is required for the mitogenic effect of thyroid-stimulating hormone (TSH) to occur. The aim of the present study was to determine whether thyroid IRS-1 content is modulated by TSH in vivo. Strikingly, hypothyroid goitrous rats, which have chronically high serum TSH levels (control, C = 2.31 ± 0.28; methimazole (MMI) 21d = 51.02 ± 6.02 ng/mL, N = 12 rats), when treated with 0.03 percent MMI in drinking water for 21 days, showed significantly reduced thyroid IRS-1 mRNA content. Since goiter was already established in these animals by MMI for 21 days, we also evaluated IRS-1 expression during goitrogenesis. Animals treated with MMI for different periods of time showed a progressive increase in thyroid weight (C = 22.18 ± 1.21; MMI 5d = 32.83 ± 1.48; MMI 7d = 31.1 ± 3.25; MMI 10d = 33.8 ± 1.25; MMI 14d = 45.5 ± 2.56; MMI 18d = 53.0 ± 3.01; MMI 21d = 61.9 ± 3.92 mg, N = 9-15 animals per group) and serum TSH levels (C = 1.57 ± 0.2; MMI 5d = 9.95 ± 0.74; MMI 7d = 10.38 ± 0.84; MMI 10d = 17.72 ± 1.47; MMI 14d = 25.65 ± 1.23; MMI 18d = 35.38 ± 3.69; MMI 21d = 31.3 ± 2.7 ng/mL, N = 9-15 animals per group). Thyroid IRS-1 mRNA expression increased progressively during goitrogenesis, being significantly higher by the 14th day of MMI treatment, and then started to decline, reaching the lowest values by the 21st day, when a significant reduction was detected. In the liver of these animals, however, a significant decrease of IRS-1 mRNA was detected after 14 days of MMI treatment, a mechanism probably involved in the insulin resistance that occurs in hypothyroidism. The increase in IRS-1 expression during goitrogenesis may represent...
Assuntos
Animais , Masculino , Ratos , Proteínas Adaptadoras de Transdução de Sinal/metabolismo , Bócio/metabolismo , Hipotireoidismo/metabolismo , Glândula Tireoide/citologia , Tireotropina/metabolismo , Proteínas Adaptadoras de Transdução de Sinal/efeitos dos fármacos , Bócio/induzido quimicamente , Hipotireoidismo/induzido quimicamente , Mitose , Metimazol/farmacologia , Ratos Wistar , Reação em Cadeia da Polimerase Via Transcriptase Reversa , RNA Mensageiro/análise , Glândula Tireoide/efeitos dos fármacos , Tireotropina/efeitos dos fármacosRESUMO
BACKGROUND: To determine thyroid gland volume and the prevalence of goiter in patients receiving long-term lithium treatment for affective disorders. METHODS: In this cross-sectional study, we performed ultrasonographic examinations in 96 patients on long-term lithium treatment, including those with bipolar, major depressive, and schizoaffective disease. Patients with documented continuous and adequate serum lithium levels for more than or equal to 6 months were recruited consecutively from the Berlin Lithium Clinic. Ultrasonographic examinations were also performed in 96 gender- and age-matched control subjects. Patients and controls were 18 years of age or older and were residents of Berlin, Germany and surrounding areas. RESULTS: Total thyroid volume was significantly greater in the lithium-treated group than among controls (23.7 ml vs. 13.6 ml). Ultrasonography detected that significantly more lithium-treated subjects had goiter than did control subjects (N=53 vs. N=19). Clinical inspection and palpation only detected goiter in 24 of the lithium-treated patients and in 12 control subjects. In a patient subgroup taking levothyroxine, the prevalence of goiter was still 37%. Patients who were not taking levothyroxine had significantly higher TSH basal levels than normal controls (2.1 mU/L vs. 1.3 mU/L). LIMITATIONS: Cross-sectional study; no control for other factors related to thyroid enlargement and goiter such as dietary issues, smoking, or iodine intake; affectively ill subjects were treated with additional psychotropic medications. CONCLUSIONS: Thyroid enlargement was found in a significant number of lithium-treated patients. Ultrasonography proved superior to palpatory inspection in detecting goiter. Regular use of ultrasonography for early detection of thyroid enlargement in patients on long-term lithium treatment is therefore recommended.